Search for brain tumor biomarkers in urine strikes gold

By Tom Ulrich

A good biomarker is one whose levels go up or down as a patient’s disease worsens or wanes. A great biomarker also gives key insights into disease development. A really great biomarker does both of these things and also serves as a treatment target.

With a protein called netrin-1, Edward Smith, MD, and Michael Klagsbrun, PhD, seem to have hit the trifecta. In a recent paper in Cancer Research, they report a clear relationship between urine netrin levels and medulloblastoma, the most common malignant brain tumor of children.

And show that netrin fuels the tumor’s invasion into healthy brain tissue.

And that blocking netrin may, at least in the laboratory, check the tumor’s spread.

From brain to bladder

For years, Smith – a brain surgeon and Boston Children’s Hospital’s director of pediatric cerebrovascular surgery – has been searching for ways to use urine to watch for relapses in children with brain tumors.


The search started when Smith attended a seminar by Marsha Moses, MD, PhD, director of the hospital’s Vascular Biology Program (VBP), who studies urine biomarkers for ovarian and breast cancer. Inspired, he started learning from her how to isolate proteins from urine and assess them as potential biomarkers.

In 2008, the pair showed that a panel of urine biomarkers correlated with the presence of a variety of brain tumors. But just knowing a tumor is there wasn’t enough for Smith. As a surgeon, he wanted to know what the tumor is doing.

“The biggest problem I face as a surgeon is invasion,” he says. “Invasive tumors put fingers out into the surrounding tissue, making them harder to operate on. They’re also harder to treat with chemotherapy and radiation and more prone to metastasis.”

While gene signatures can tell us something about a medulloblastoma’s behavior, reading those signatures requires having tumor tissue on hand. Gene signatures also can’t help track a brain tumor’s response to treatment – at least not without taking additional biopsies – or raise an alarm if a tumor returns. Those are things that are best detected using markers pulled from an easily collected fluid. And urine is probably the easiest, least invasive fluid of all.

Marker hunters

Michael Klagsbrun, PhD
Michael Klagsbrun, PhD

To home in on urine markers that could provide intel on tumor presence and behavior, Smith teamed up with Klagsbrun. For more than 40 years, Klagsbrun has been working in the VBP to tease apart the intricate web of chemical signals influencing blood vessel growth (angiogenesis) and cancer development. He is particularly interested in semaphorins, a family of axon guidance factors that influences nerve growth during development and also seem to play a role in angiogenesis.

Netrin is also an axon guidance factor. During fetal development, netrin and semaphorins work in opposition. Netrin creates a trail of chemical breadcrumbs that young nerve fibers follow as they grow. Semaphorins block or deflect nerve growth.

“There’s a balance between them,” Klagsbrun says, “between pro-growth and anti-growth.” Or, as Smith puts it, “Netrin is like the gas, semaphorins the brakes.”

Looking at cell lines, the pair found that netrin holds a great deal of pro-growth sway over medulloblastomas. Adding netrin to medulloblastoma cell lines caused a jump in tumor cell invasion while also activating a signaling pathway known to be involved in cancer development (thus making netrin a potential therapeutic target.) At the same time, blocking netrin using a variety of techniques (e.g., receptor blockade, siRNA, neutralizing antibodies and small molecules) reduced invasion.

Nimbler tumor screening

Michael Klagsbrun, PhD
Edward Smith, MD

Turning to patient samples, Smith and Klagsbrun found that the tumor cells of one patient produced significantly more netrin than adjacent, normal brain cells. They also found that urine from 16 medulloblastoma patients contained between five and 10 times as much netrin as urine from 12 healthy controls, and that urine netrin levels drop after a patient undergoes surgery.

As a bonus, urine levels alone could single out patients with highly invasive tumors, the ones that had spread more aggressively.

“You can’t always see on an MRI if a child will have an invasive tumor,” Smith notes. “But here we saw a gradient of netrin levels that increased as we looked from healthy controls across to high-risk patients.”

For the moment, Smith envisions cheaper, measurable and more frequent screening of medulloblastoma patients after treatment.

“Measuring urine netrin could help guide decisions about when a patient might need a scan and additional treatment,” he says. “The ‘pie-in-the-sky’ scenario would be to use urine biomarkers like netrin to tailor a patient’s treatment regimen. Because urine proteins change more quickly than scans, we could be more nimble with our treatment approach.”

RSS From Medical Design & Outsourcing

  • Emuge expands solid carbide thread mill program with new 3XD sizes
    Emuge is now offering an expanded line of Solid Carbide Thread Mills in their popular THREADS-ALL Program, to include new 3XD sizes designed for maximum reach. A total of 17 new sizes have been added, from miniature to standard size tools, providing maximum versatility in a wide range of thread milling applications. The 3XD THREADS-ALL […]
  • Start of helpful humanoid robots? CITEC uses compact LDS component as sensor array
    Editor’s Note: LaserMicronics, a service provider for laser-based manufacturing, has released the whitepaper “Robot hand with a sensitive touch: LDS tactile sensors for sensorimotor skills.” The paper describes a 2014 project from the CITEC department at Bielefeld University in Bielefeld, Germany, where researchers created a tactile sensor resembling a human fingertip. The sensor was then […]
  • Nature meets technology: Festo’s BionicANTs cooperate to solve a common task
    Editor’s Note: Festo, an industrial control and automation company, has released the whitepaper “BionicANTs: Cooperative behavior based on a natural model.” The paper describes the BionicANT, a creation of Festo engineers that duplicates the physical anatomy of its natural counterpart and reproduces the insect’s cooperative behavior. Festo engineers have used the delicate anatomy of an […]
  • Acorn Regulatory streamlines approval process drug-device manufacturers
    Acorn Regulatory, an ISO-certified medical device and pharmaceutical consulting firm, is streamlining procedures for U.S. manufacturers of drug-device combinations with customized programs that successfully overcome challenges in meeting European regulatory approvals. Focusing on small to mid-size companies, Acorn Regulatory has put in place a comprehensive step-by-step process that provides the correct regulatory pathway for medical […]
  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]

Leave a Reply